痛风与心房颤动患者缺血性卒中风险:全国队列研究
芬兰FinACAF全国注册联动队列纳入2007—2018年新发心房颤动患者229 565例,其中6 910例(3.0%)有痛风史。痛风与缺血性卒中发生率升高相关(校正发病率比1.12,95%CI 1.02-1.24),降尿酸治疗与卒中率降低30%相关。
要点
- 痛风是心房颤动患者缺血性卒中的重要危险因素,或可改善风险分层。
- 校正后痛风患者卒中发生率比为1.12(95%CI 1.02-1.24)。
- 合并痛风的心房颤动患者使用降尿酸治疗与卒中率降低30%相关。
核心结论
- 痛风是心房颤动患者缺血性卒中的重要危险因素,考虑痛风或可改善卒中风险分层。
- 降尿酸治疗与卒中风险降低相关,提示痛风是心房颤动患者可干预的危险因素。
研究设计与样本
- FinACAF全国注册联动队列纳入芬兰2007—2018年各级诊疗的全部心房颤动患者。
- 共识别新发心房颤动患者229 565例,女性占50.0%,平均年龄72.7岁,平均随访4.0年。
- 依据诊断编码与药房索赔数据评估痛风及降尿酸治疗与缺血性卒中发病的关联。
主要发现
- 6 910例(3.0%)有痛风史,16 296例(7.1%)发生缺血性卒中。
- 痛风与更高卒中率相关:未校正发病率比1.35(95%CI 1.22-1.49),校正后1.12(95%CI 1.02-1.24)。
- 仅限未抗凝随访的分析结果一致且点估计略高:未校正1.88(95%CI 1.63-2.17),校正1.26(95%CI 1.09-1.46)。
- 痛风合并心房颤动患者中,降尿酸治疗的时间依赖暴露与卒中率降低30%相关。
- 未抗凝痛风患者粗卒中率:CHA2DS2-VA评分0、1、≥2分别为每100患者年1.5、1.0、4.8。
临床怎么用
- 对心房颤动患者评估卒中风险时可考虑纳入痛风病史以辅助风险分层。
- 对合并痛风的心房颤动患者,可考虑降尿酸治疗作为潜在可干预的卒中风险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gout is an emerging cardiovascular risk factor. We aimed to assess whether gout is associated with an increased risk of stroke in patients with atrial fibrillation (AF). METHODS: The nationwide registry-linkage FinACAF study (Finnish Anticoagulation in Atrial Fibrillation) included all patients with AF in Finland between 2007 and 2018 from all levels of care. Based on diagnosis codes and pharmacy claims data, the association of gout and urate-lowering therapy with the incidence of ischemic stroke was assessed. RESULTS: We identified 229 565 patients with new-onset AF (50.0% female; mean age, 72.7 years; mean follow-up, 4.0 years), of whom 6 910 (3.0%) had a history of gout. A total of 16 296 (7.1%) patients experienced an ischemic stroke. Gout was associated with higher stroke rates in both unadjusted and adjusted analyses (incidence rate ratio, 1.35 [95% CI, 1.22-1.49] and incidence rate ratio, 1.12 [95% CI, 1.02-1.24], respectively). Analyses restricted to follow-up without anticoagulation yielded consistent results with slightly higher point estimates (incidence rate ratio, 1.88 [95% CI, 1.63-2.17] unadjusted; incidence rate ratio 1.26 [95% CI, 1.09-1.46] adjusted). In patients with gout and AF, time-dependent exposure to urate-lowering therapy was associated with a 30% lower stroke rate. Nonanticoagulated crude stroke rates were 1.5, 1.0, and 4.8 per 100 patient-years for gout patients with CHA2DS2-VA scores of 0, 1, and ≥2, respectively. CONCLUSIONS: Gout is an important risk factor for ischemic stroke in patients with AF, and considering gout could improve stroke risk stratification. Urate-lowering therapy was associated with reduced stroke risk, suggesting that gout is a modifiable risk factor in patients with AF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04645537.
引用
- Palomäki A, Langén V, Airaksinen KEJ, et al. Gout and Risk of Ischemic Stroke in Patients With Atrial Fibrillation: A Nationwide Cohort Study. Stroke. 2026. PMID: 42267424. doi:10.1161/STROKEAHA.126.055194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。